Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1 or CD279)
have noticeably improved the treatment landscape of advanced cancer patients. Nivolumab …

MDM4 is a homologue of MDM2, serving cooperatively as the negative regulator of tumor
suppressor p53. Under the shadow of MDM2 inhibitors, limited efforts had been put into the …

MDM2 and MDM4 are key negative regulators of p53, an important protein involved in
several cell processes (eg cell cycle and apoptosis). Not surprisingly, the p53 tumor …

Inhibition of the MDM2/X-p53 interaction is recognized as a potential anti-cancer strategy,
including the treatment of glioblastoma (GB). In response to cellular stressors, such as DNA …

Simple Summary Glioblastoma is a type of brain cancer that remains incurable. Despite
multiple past and ongoing preclinical studies and clinical trials, involving adjuvants to the …

Treatment of metastatic disease remains among the most challenging tasks in oncology.
One of the early events that predicts a poor prognosis and precedes the development of …

Despite recent clinical progress in peptide-based dual inhibitors of MDM2/4, small-molecule
ones with robust antitumor activities remain challenging. To tackle this issue, 31 (YL93) was …

MDM2 and MDM4 cooperatively and negatively regulate p53, while this pathway is often
hijacked by cancer cells in favor of their survival. Blocking MDM2/p53 interaction with small …

Colorectal cancer (CRC) often involves wild-type p53 inactivation by MDM2 and MDM4
overexpression, promoting tumor progression and resistance to 5-fluoruracil (5-FU) …

Primary brain tumors are a leading cause of death worldwide and are characterized by
extraordinary heterogeneity and high invasiveness. Current drug and radiotherapy therapies …